IWK Health Centre

Running trials

• Recruiting

  Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation

  NCT06942039· Early phase 1· Source

• Recruiting

  CANnabinoids in Pediatric ONCology

  NCT05754840· Phase 1/2· Source

• Recruiting

  A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

  NCT06124157· Phase 2· Source

• Recruiting

  A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)

  NCT06401330· Phase 3· Source

• Recruiting

  Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma

  NCT06647953· Phase 3· Source

• Recruiting

  A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma

  NCT06368817· Phase 2· Source

• Recruiting

  Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

  NCT06172296· Phase 3· Source

• Recruiting

  CfDNA in Hereditary And High-risk Malignancies 2

  NCT06726642· Source

• Recruiting

  A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease

  NCT05509777· Phase 3· Source

• Recruiting

  A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease

  NCT05923073· Phase 3· Source

• Active, not recruiting

  A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia

  NCT05761171· Phase 2· Source

• Active, not recruiting

  Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma

  NCT05602194· Phase 3· Source

• Recruiting

  A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

  NCT05675410· Phase 3· Source

• Recruiting

  A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss

  NCT05382338· Phase 3· Source

• Active, not recruiting

  Firefighters Preventing Cancer Online Training Program

  NCT05745246· Source

• Recruiting

  Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma

  NCT05304585· Phase 3· Source

• Active, not recruiting

  A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)

  NCT05099003· Phase 1/2· Source

• Recruiting

  The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

  NCT04726241· Phase 1/2· Source

• Recruiting

  Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma

  NCT05235165· Phase 3· Source

• Active, not recruiting

  Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

  NCT04759586· Phase 3· Source

• Active, not recruiting

  A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma

  NCT04994132· Phase 3· Source

• Active, not recruiting

  Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis

  NCT04624230· Phase 3· Source

• Recruiting

  A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT

  NCT04684368· Phase 2· Source

• Recruiting

  Hypertrophic Cardiomyopathy Registry, Biobank and Imaging Data Repository

  NCT05100420· Source

• Active, not recruiting

  Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)

  NCT04385277· Phase 2· Source

• Active, not recruiting

  Mobile Health and Social Media Physical Activity Intervention Among Adolescent and Young Adult Childhood Cancer Survivors, the StepByStep Study

  NCT04089358· Phase 3· Source

• Recruiting

  A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT

  NCT04322318· Phase 2· Source

• Recruiting

  A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

  NCT04293562· Phase 3· Source

• Active, not recruiting

  A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma

  NCT03871257· Phase 3· Source

• Active, not recruiting

  Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia

  NCT03817398· Phase 2· Source

• Recruiting

  Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

  NCT03959085· Phase 3· Source

• Active, not recruiting

  Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia

  NCT03834961· Phase 2· Source

• Active, not recruiting

  Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma

  NCT03794349· Phase 2· Source

• Active, not recruiting

  A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

  NCT03914625· Phase 3· Source

• Active, not recruiting

  Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations

  NCT03581292· Phase 2· Source

• Active, not recruiting

  Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway.

  NCT03363217· Phase 2· Source

• Active, not recruiting

  Cell-free DNA in Hereditary And High-Risk Malignancies 1

  NCT04261972· Source

• Active, not recruiting

  Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery

  NCT03533582· Phase 3· Source

• Recruiting

  Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

  NCT03126916· Phase 3· Source

• Active, not recruiting

  Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma

  NCT02724579· Phase 2· Source

• Active, not recruiting

  Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

  NCT03007147· Phase 3· Source

• Active, not recruiting

  Late Effects After Treatment in Patients With Previously Diagnosed High-Risk Neuroblastoma

  NCT03057626· Source

• Recruiting

  Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

  NCT03067181· Phase 3· Source

• Active, not recruiting

  Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma

  NCT02567435· Phase 3· Source

• Active, not recruiting

  Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome

  NCT02521493· Phase 3· Source

• Recruiting

  Project: Every Child for Younger Patients With Cancer

  NCT02402244· Source

• Active, not recruiting

  Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia

  NCT02339740· Phase 3· Source

• Active, not recruiting

  Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma

  NCT02166463· Phase 3· Source

• Recruiting

  Simple Bone Cysts in Kids

  NCT02193841· Phase 3· Source

• Active, not recruiting

  Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia

  NCT02101853· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers20 recruiting
• Acute lymphoblastic leukaemia3 recruiting
• Neuroblastoma3 recruiting
• Acute myeloid leukemia2 recruiting
• Crohn's disease2 recruiting
• Kidney cancer2 recruiting
• Ovarian cancer2 recruiting
• Sarcoma2 recruiting
• Gastric and esophageal cancer1 recruiting
• Hypertrophic cardiomyopathy1 recruiting
• Lung cancer1 recruiting
• Myelodysplastic syndromes1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Neuroendocrine tumours1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  The Effect of In-utero Exposure to Metformin in 5-11 Year Old Offspring of Mothers in the MiTy Trial

  NCT05025852· Source

• Terminated

  Personalized AZithromycin/metronidAZole Therapy in Pediatric Crohn's Disease (CD)

  NCT04186247· Phase 2· Source

• Completed

  Closed-loop Insulin Delivery In Type 1 Diabetes Pregnancies (CIRCUIT)

  NCT04902378· Source

• Completed

  HRQL and Symptom Assessment for Patients With DIPG or Recurrent and Re-irradiated Brain Tumours and Their Caregivers

  NCT04670016· Source

• Completed

  The Pain Squad+ Smartphone App To Support Real-Time Pain Management for Adolescents With Cancer

  NCT03632343· Source

• Completed

  Biospecimen Analysis in Determining Effects of Chemotherapy on Fertility in Osteosarcoma Survivors

  NCT03206450· Source

• Completed

  Re-Irradiation of Progressive or Recurrent DIPG

  NCT03126266· Source

• Completed

  Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement

  NCT02828358· Phase 2· Source

• Completed

  Carvedilol in Preventing Heart Failure in Childhood Cancer Survivors

  NCT02717507· Phase 2· Source

• Completed

  Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma

  NCT02470091· Phase 2· Source

• Completed

  Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery

  NCT02180867· Phase 2/3· Source

• Completed

  Blood Sample Markers of Reproductive Hormones in Assessing Ovarian Reserve in Younger Patients With Newly Diagnosed Lymphomas

  NCT01793233· Source

• Completed

  Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

  NCT01798004· Phase 1· Source

• Completed

  Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma

  NCT01553149· Phase 2· Source

• Completed

  Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors

  NCT01602666· Phase 2· Source

• Completed

  Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations

  NCT02883049· Phase 3· Source

• Completed

  Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

  NCT01371981· Phase 3· Source

• Completed

  Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma

  NCT01236560· Phase 2/3· Source

• Completed

  Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma

  NCT01231906· Phase 3· Source

• Completed

  Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma

  NCT01190930· Phase 3· Source

• Completed

  Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma

  NCT01096368· Phase 3· Source

• Completed

  Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer

  NCT00980460· Phase 3· Source

• Completed

  Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor

  NCT00945009· Phase 3· Source

• Completed

  A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) or With Ph+ Leukemias Resistant or Intolerant to Imatinib

  NCT00777036· Phase 2· Source

• Completed

  Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

  NCT00557193· Phase 3· Source

• Completed

  Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma

  NCT00336024· Phase 3· Source

• Completed

  Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma/PNET

  NCT00392327· Phase 3· Source

• Completed

  Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor

  NCT00379340· Phase 3· Source

• Completed

  Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

  NCT00408005· Phase 3· Source

• Completed

  Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor

  NCT00352534· Phase 3· Source

• Completed

  Treating Young Patients With Newly Diagnosed, Low Stage, Lymphocyte Predominant Hodgkin Disease

  NCT00107198· Phase 2· Source

• Completed

  Study of Kidney Tumors in Younger Patients

  NCT00898365· Source

• Completed

  Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma

  NCT00085735· Phase 3· Source

• Completed

  Genetic Analysis in Identifying Late-Occurring Complications in Childhood Cancer Survivors

  NCT00082745· Source

• Completed

  Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma

  NCT00026312· Phase 3· Source

• Completed

  Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma

  NCT00904241· Source